AbbVie Announces Approval for Epcoritamab in Combination Therapy for Follicular Lymphoma

AbbVie's Breakthrough Approval

AbbVie, in collaboration with Genmab, has successfully obtained partial changes to the manufacturing and marketing approval for its dual-specific antibody, Epcoritamab (brand name: Epcoritamab (genetically engineered)), for the treatment of relapsed or refractory follicular lymphoma (FL) in combination with Rituximab and Lenalidomide (R2). This development brings a much-needed new treatment option for patients suffering from this difficult-to-treat disease.

Follicular lymphoma is recognized as the second most prevalent type of non-Hodgkin lymphoma (NHL) and poses significant challenges in treatment when it recurs. Currently, it is estimated that around 19,000 patients in Japan are living with FL. These patients often experience repeated relapses, resulting in progressively lower response rates to existing therapies and shorter durations of response. The need for new treatment options is particularly highlighted for those with relapsed or refractory FL, as standard treatment protocols have yet to be established.

Important Regulatory Milestone

The approval for Epcoritamab in combination with R2 follows the results obtained from the international phase III EPCORE FL-1 clinical trial, which includes data from Japan. The trial aimed to assess the efficacy and safety of this combination therapy compared to R2 alone. This new therapy offers a fixed-duration administration method targeting FL patients who have undergone at least one systemic therapy.

According to Thiago Campos Rodrigues, President of AbbVie, this approval marks a crucial step forward, providing Japanese patients with relapsed or refractory FL a significant new treatment option. He emphasized the persistent high medical needs remaining in this disease area and expressed hopes for Epcoritamab and R2 combination therapy to become a meaningful choice for patients and healthcare professionals alike. AbbVie, together with Genmab, remains committed to delivering innovative treatments to patients in dire need as swiftly as possible.

Clinical Study Insights

The approval is predicated on findings from the EPCORE FL-1 trial, where the combination therapy of Epcoritamab and R2 exhibited a 79% reduction in the risk of disease progression or death compared with R2 therapy alone (Hazard Ratio [HR]: 0.21; 95% Confidence Interval [CI]: 0.13-0.33; p<0.0001). The median progression-free survival (PFS) was also noted to be impressive, where patients receiving the combination therapy had an indefinite PFS estimation and those on R2 alone had a median PFS of 11.2 months (95% CI: 10.5 months-NE).

In terms of treatment efficacy, out of 488 patients enrolled in the EPCORE FL-1 trial, 95.7% of the 116 patients treated with Epcoritamab and R2 achieved a response, compared to 81.0% of those who received only R2.

Some side effects observed in patients treated with Epcoritamab included neutropenia, cytokine release syndrome, and injection site reactions, though most were manageable.

Overview of Epcoritamab

Epcoritamab is an IgG1 dual-specific antibody specifically designed to target and activate T cells against CD20-positive B cells. This innovative therapy showcases a significant shift in treatment methodologies, especially in hemato-oncology. With over 65 regulatory approvals in various countries for targeted indications, Epcoritamab (now approved as Epcoritamab in the U.S. and TEPKINLY in the EU) is part of a broader pipeline aimed at addressing significant unmet needs in cancer treatment.

AbbVie’s dedication to innovative oncology solutions continues, with a commitment to develop promising therapies aimed at improving patient outcomes across multiple lines of treatment in various malignancies. As part of this, data from ongoing trials like EPCORE DLBCL-2, which seeks to evaluate Epcoritamab in combination with standard therapies, is eagerly anticipated for future announcements.

For more information about AbbVie and its cancer research and therapies, you can visit AbbVie Oncology.

Conclusion

The approval of Epcoritamab offers hope to patients battling difficult FL, ushering in new possibilities in oncological therapeutics. AbbVie’s ongoing collaboration with Genmab signifies the importance of partnerships in swiftly delivering effective treatment solutions to those in need.